{
  "id": "5e44caaf48dab47f26000024",
  "type": "yesno",
  "question": "Should Lubeluzole be used for treatment of ischemic stroke?",
  "ideal_answer": "No. Lubeluzole failed to consistently show an efficacy in the treatment of acute stroke and should not be used.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29550817",
    "http://www.ncbi.nlm.nih.gov/pubmed/9412611",
    "http://www.ncbi.nlm.nih.gov/pubmed/11062273",
    "http://www.ncbi.nlm.nih.gov/pubmed/11869612",
    "http://www.ncbi.nlm.nih.gov/pubmed/8553408",
    "http://www.ncbi.nlm.nih.gov/pubmed/12038658",
    "http://www.ncbi.nlm.nih.gov/pubmed/28939972",
    "http://www.ncbi.nlm.nih.gov/pubmed/9619701"
  ],
  "snippets": [
    {
      "text": "Lubeluzole showed promising neuroprotective effects in animal stroke models, but failed to show benefits in acute ischemic stroke in humans. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28939972",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, clinical research on lubeluzole is now at a standstill, since lubeluzole seems to be associated with the acquired long QT syndrome and ventricular arrhythmias. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29550817",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ten classes of neuroprotective agents have reached phase III efficacy trials but have shown mixed results. They included calcium channel antagonists, NMDA receptor antagonists, lubeluzole, CDP-choline, the free radical scavenger tirilazad and ebselen, enlimomab, GABA agonist clomethiazole, the sodium channel antagonist fosphenytoin, magnesium, glycine site antagonist GV150526 and piracetam. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12038658",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: This study failed to show an efficacy of lubeluzole in the treatment of acute stroke. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11062273",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Overall, of all treated patients, 401 (22.5%) died: 203 (22.5%) in the lubeluzole group and 198 (22.4%) with placebo. Of all subjects treated, 853 (95%) on lubeluzole and 826 (93%) on placebo reported an adverse event during their treatment period or within the next 2 days after discontinuation of treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11062273",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Treatment with lubeluzole within 6 hours of the onset of ischemic stroke had a nonsignificant effect on mortality and resulted in improved clinical outcome compared with placebo, with no safety concerns.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9412611",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: The overall mortality rate at 12 weeks for lubeluzole-treated patients was 20.7% compared to 25.2% for placebo-treated patients (NS). Controlling for relevant covariates, the degree of neurological recovery (NIHSS) at week 12 significantly favored lubeluzole over placebo (P = .033). Lubeluzole treatment similarly resulted in significantly greater improvements in functional status (Barthel Index) (P = .038) and overall disability (Rankin Scale) (P = .034) after 12 weeks. A global test statistic confirmed that lubeluzole-treated patients had a more favorable clinical outcome at 12 weeks (P = .041).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9412611",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In patients with acute ischemic stroke, the dosage regimen of 7.5 mg over 1 hour followed by 10 mg/d of intravenous lubeluzole is safe and statistically significantly reduced mortality. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8553408",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nTreatment with lubeluzole within 6 hours of the onset of ischemic stroke had a nonsignificant effect on mortality and resulted in improved clinical outcome compared with placebo, with no safety concerns.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9412611",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Lubeluzole, given in the acute phase of ischaemic stroke, is not associated with a significant reduction of death or dependency at the end of scheduled follow-up period but seems to be associated with a significant increase of heart-conduction disorders (Q-T prolonged >450 msec).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11869612",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment with lubeluzole within 6 hours of the onset of ischemic stroke had a nonsignificant effect on mortality and resulted in improved clinical outcome compared with placebo, with no safety concerns.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9412611",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the overall study population, treatment with intravenous lubeluzole within 6 h of the onset of ischaemic stroke did not affect mortality or clinical outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9619701",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}